Advertisement

Limited-Disease Small-Cell Lung Cancer

  • Branislav Jeremić
  • Željko Dobrić
  • Francesc Casas
Chapter
Part of the Medical Radiology book series (MEDRAD)

Abstract

About one-third of all patients with small cell lung cancer present with their disease confined to thorax. In the last two decades, combined radiation therapy and chemotherapy have been considered standard treatment option in this disease. This particularly became evident when radical thoracic radiation therapy was combined with concurrent platinum-etoposide chemotherapy. Prophylactic cranial irradiation was also shown to be important part of the overall treatment approach and is suggested as standard treatment option in the last decade. Several questions, however, remained in focus of clinical investigations in the recent decades with no clear answers provided. In particular, investigators embarked on evaluating the timing of administration of radiation therapy and chemotherapy in combined modality approach. Several prospective randomized trials and several meta-analyses showed that there is an advantage for early administration of the two modalities, especially using concurrent approach. While landmark Intergroup study clearly showed benefit of BID fractionation over QD fractionation, two ongoing studies further built on the question of optimization of dose and fractionation issue in this setting. Finally, issue of tumor volumes to be used during the radiation therapy course remain suboptimally investigated due to lack of clinical studies investigating it and, therefore, poor guidelines for daily clinical practice.

Keywords

Prophylactic Cranial Irradiation Elective Nodal Irradiation Hyperfractionated Radiation Therapy Combine Modality Approach Hypofractionated Radiation Therapy Regimen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Ali MA, Kraut MJ, Valdivieso M, Herskovic AM, Du W, Kalemkerian GP (1998) Phase II study of hyperfractionated radiotherapy and concurrent weekly alternating chemotherapy in limited-stage small cell lung cancer. Lung Cancer 22:39–44PubMedCrossRefGoogle Scholar
  2. Amarasena IU, Walters JA, Wood-Baker R, Fong K (2008) Platinum versus non-platinum chemotherapy regimens for small cell lung cancer. Cochrane Database Syst Rev.4:CD006849Google Scholar
  3. Ardizzoni A, Tjan-Heijnen VCG, Postmus PE, Buchholz E, Biesma B, Karnicka-Mladowska H, Dziadziuszko R, Burghouts J, van Meerbeck JP, Gans S, Legrand C, Debruyne C, Giaccone G, Manegold C (2002) Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for research and treatment of cancer—lung cancer group phase III trial–08923. J Clin Oncol 20:3947–3955PubMedCrossRefGoogle Scholar
  4. Arriagada R, Le Chevalier T, Pignon JP, Riviere A, Monnet I, Chomy P, Tuchais C, Tarayre M, Ruffie P (1993) Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med 25:1848–1852CrossRefGoogle Scholar
  5. Auperin A, Arriagada R, Pignon JP, Le Pechoux C, Gregor A, Stephens RJ, Kristjansen PE, Johnson BE, Ueoka H, Wagner H, Aisner J (1999) Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission prophylactic cranial irradiation overview collaborative group. N Engl J Med 341:476–484PubMedCrossRefGoogle Scholar
  6. Beith JM, Clarke SJ, Woods RL, Bell DR, Levi JA (1996) Long-term follow-up of a randomised trial of combined chemoradiotherapy induction treatment, with and without maintenance chemotherapy in patients with small cell carcinoma of the lung. Eur J Cancer 32A:438–443PubMedCrossRefGoogle Scholar
  7. Birch R, Greco F, Hainsworth J (2000) Preliminary results of a randomized study comparing etoposide and carboplatin with or without paclitaxel in newly diagnosed small cell lung cancer. Proc Am Soc Clin Oncol 19:490 (Abstract)Google Scholar
  8. Bleehen NM, Fayers PM, Girling DJ, Stephens RJ (1989) Controlled trial of twelve versus six courses of chemotherapy in the treatment of small-cell lung cancer. Br J Cancer 59:584–590CrossRefGoogle Scholar
  9. Bogart JA, Herndon JE, Lyss AP, Watson D, Miller AA, Lee ME, Turrisi AT, Green MR, Cancer and Leukemia Group B study 39808 (2004) 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of cancer and leukemia group B study 39808. Int J Radiat Oncol Biol Phys 59:460–468PubMedCrossRefGoogle Scholar
  10. Bonner JA, Sloan JA, Shanahan TG, Brooks BJ, Marks RS, Krook JE, Gerstner JB, Maksymiuk A, Levitt R, Mailliard JA, Tazelaar HD, Hillman S, Jett JR (1999) Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma. J Clin Oncol 17:2681–2691PubMedGoogle Scholar
  11. Bremnes RM, Sundstrom S, Vilsik J, Aasebo U (2001) Multicenter phase II trial of palcitaxel, cisplatin, and etposide with concurrent radiation for limited-stage small cell lung cancer. J Clin Oncol 19:3532–3538PubMedGoogle Scholar
  12. Byrne MJ, Van Hazel G, Trotter J, Cameron F, Shepherd J, Cassidy B, Gebski V (1989) Maintenance chemotherapy in limited small cell lung cancer: a randomised controlled clinical trial. Br J Cancer 59:584–590CrossRefGoogle Scholar
  13. Choi NC, Carey RR (1989) Importance of radiation dose in achieving improved locoregional tumor control in small-cell lung carcinoma: an update. Int J Radiat Oncol Biol Phys 17:307–310PubMedCrossRefGoogle Scholar
  14. Choi N, Herndon J, Rosenman J, Carey RW, Chung CT, Bernard S, Leone L, Seagren S, Green M (1998) Phase I study to determine the maximum tolerated dose of radiation in standard daily and accelerated twice daily radiotherapy schedules with concurrent chemotherapy for limited stage small cell lung cancer : CALGB 8837. J Clin Oncol 16:3528–3536PubMedGoogle Scholar
  15. Cohen MH, Broder LE, Fossieck BE, Ihde DC, Minna JD (1977) Intensive chemotherapy of small cell bronchogenic carcinoma. Cancer Treat Rep 61:349–354PubMedGoogle Scholar
  16. Cohen MH, Ihde DC, Bunn PA Jr, Fossieck BE Jr, Matthews MJ, Shackney SE, Johnston-Early A, Makuch R, Minna JD (1979) Cyclic alternating combination chemotherapy for small cell bronchogenic carcinoma. Cancer Treat Rep 62:163–170Google Scholar
  17. Cullen M, Morgan D, Gregory W, Robinson M, Cox D, McGivern D, Ward M, Richards M, Stableforth D, Macfarlane A (1986) Maintenance chemotherapy for anaplastic small cell carcinoma of the bronchus: a randomised, controlled trial. Cancer Chemother Pharmacol 17:157–160PubMedCrossRefGoogle Scholar
  18. Curran WJ (2001) Combined-modality therapy for limited-stage small cell lung cancer. Sem Oncol 28:14–22CrossRefGoogle Scholar
  19. De Ruysscher D, Bremer RH, Koppe F, Wanders S, van Haren E, Hochstenbag M, Geeraedts W, Pitz C, Simons J, ten Velde G, Dohmen J, Snoep G, Boersma L, Verschueren T, van Baardwijk A, Dehing C, Pijls M, Minken A, Lambin P (2006) Omission of elective node irradiation on basis of CT-scans in patients with limited disease small cell lung cancer: a phase II trial. Radiother Oncol 80:307–312PubMedCrossRefGoogle Scholar
  20. Edelmen MJ, Chansky K, Gaspar LE, Leigh B, Weiss GR, Taylor SA, Crowley J, Livingston R, Gandara DR (2004) Phase II trial of cisplatin/etoposide and concurrent radiotherapy followed by paclitaxel/carboplatin consolidation for limited small-cell lung cancer: southwest Oncology Group 9713. J Clin Oncol 22:127–132CrossRefGoogle Scholar
  21. Einhorn LH, Crawford J, Birch R, Omura G, Johnson DH, Greco FA (1988) Cisplatin plus etoposid consolidation following cyclophosphamide, doxorubicin, and vincristine in limited small-cell lung cancer. J Clin Oncol 6:451–456PubMedGoogle Scholar
  22. El Sharouni SY, Kal HB, Barten-Van Rijbroek A, Struikmans H, Battermann JJ, Schramel FM (2009) Concurrent versus sequential chemotherapy and radiotherapy in limited disease small cell lung cancer: a retrospective comparative study. Anticancer Res 29:5219–5224PubMedGoogle Scholar
  23. Ettinger DS, Berkey BA, Abrams RA, Fontanesi J, Machtay M, Duncan PJ, Curran WJ Jr, Movsas B, Byhardt RW, Radiation Therapy Oncology Group 9609 (2005) Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a radiation therapy oncology group 9609 phase II study. J Clin Oncol 23:4991–4998PubMedCrossRefGoogle Scholar
  24. Figueredo AT, Hryniuk WM, Strautmanis I, Frank G, Rendell S (1985) Cotrimoxazole prophylaxis during high-dose chemotherapy of small-cell lung cancer. J Clin Oncol 3:54–64PubMedGoogle Scholar
  25. Fried DB, Morris DE, Poole C, Rosenman JG, Halle JS, Detterbeck FC, Hensing TA, Socinski MA (2004) Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol 22:4837–4845PubMedCrossRefGoogle Scholar
  26. Fukuoka M, Furuse K, Saijo N, Nishiwaki Y, Ikegami H, Tamura T, Shimoyama M, Suemasu K (1991) Randmoized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 83:855–861PubMedCrossRefGoogle Scholar
  27. Gatzmeier U, von Pawel J, Macha H (2000) A phase III trial of taxol, etoposide phosphate and carboplatin (TEC) versus carboplatin, etoposide phosphate, and vincristive (CEV) in previously untreated small cell lung cancer. Proc Am Soc Clin Oncol 19:483 (Abstract)Google Scholar
  28. Giaccone G, Dalesio O, McVie GJ, Kirkpatrick A, Postmus PE, Burghouts JT, Bakker W, Koolen MG, Vendrik CP, Roozendaal KJ (1993) Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. J Clin Oncol 11:1230–1240PubMedGoogle Scholar
  29. Goldie JG, Coldman AJ (1979) A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63:1727–1735PubMedGoogle Scholar
  30. Green RA, Humphrey E, Close H, Patno ME (1969) Alkylating agents in bronchogenic carcinoma. Am J Med 46:516–525PubMedCrossRefGoogle Scholar
  31. Greenlee RT, Murray T, Bolden S, Wingo PA (2000) Cancer statistics 2000. CA Cancer J Clin 50:7–33PubMedCrossRefGoogle Scholar
  32. Hanna N, Ansari R, Fisher W, Shen J, Jung S-H, Sandler A (2002) Etoposide, ifosfamide and cisplatin (VIP) plus concurrent radiation therapy for previosuly untreated limited small cell lung cancer (SCLC) : a Hoosier oncology group (HOG) phase II study. Lung Cancer 35:293–297PubMedCrossRefGoogle Scholar
  33. Huncharek M, McGarry R (2004) A meta-analysis of the timing of chest irradiation in the combined modality treatment of limited-stage small cell lung cancer. Oncologist 9:665–762PubMedCrossRefGoogle Scholar
  34. Ihde DC, Pass HI, Glatstein EJ (1993) Small cell lung cancer. In: DeVita V, Hellman S, Rosenberg S (eds) Cancer—principles and practice of oncology. JB Lipincott Co., Philadelphia, pp 723–758Google Scholar
  35. Jeremic B (2006) Timing of concurrent radiotherapy and chemotherapy in limited-disease small-cell lung cancer: “meta-analysis of meta-analyses”. Int J Radiat Oncol Biol Phys 64:981–982PubMedCrossRefGoogle Scholar
  36. Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S (1997) Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small cell lung cancer. J Clin Oncol 15:893–900PubMedGoogle Scholar
  37. Jeremic B, Shibamoto Y, Nikolic N, Milicic B, Milisavljevic S, Dagovic A, Aleksandrovic J, Radosavljevic-Asic G (1999) The role of radiation therapy in the combined modality treatment of patients with extensive disease small-cell lung cancer (ED SCLC): a randomized study. J Clin Oncol 17:2092–2099PubMedGoogle Scholar
  38. Johnson BE, Bridges JD, Sobezeck M, Gray J, Linnoila RI, Gazdar AF, Hankins L, Steinberg SM, Edison M, Frame JN, Pass H, Nesbitt J, Holden D, Mulshine JL, Glatstein E, Ihde DC (1996a) Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine. J Clin Oncol 14:806–813Google Scholar
  39. Johnson DH, Kim K, Sause W (1996b) Cispaltin (p), etoposide (e) + thoracic radiotherapy (TRT) administered once or twice daily (bid) in limited stage (LS) small cell lung caner (sclc): final report of intergroup trial 0096. Proc Am Soc Clin Oncol 15:374Google Scholar
  40. Kamath SS, McCarley DL, Zlotecki RA (1998) Decreased metastasis and improved survival with early thoracic radiotherapy and prophylactic cranial irradiation in combined modality treatment of limited-stage small cell lung cancer. Radiat Oncol Investig 6:226–232PubMedCrossRefGoogle Scholar
  41. Kies MS, Mira JG, Crowley JJ, Chen TT, Pazdur R, Grozea PN, Rivkin SE, Coltman CA Jr, Ward JH, Livingston RB (1987) Multimodal therapy for limited small cell lung cancer: a randomized study of indcution combination chemotherapy with or without thoracic radiation in complete responders; and with widefield versus reduced voleume radiation in partial responders: a southwest oncology group study. J Clin Oncol 5:592–600PubMedGoogle Scholar
  42. Komaki R, Swann S, Ettinger D (2003) Phase I dose-escalation study of thoracic irradiation with concurrent chemotherapy for patients with limited small cell lung cancer (LSCLC): radiation therapy oncology group (RTOG) protocol 9712. Proc Am Soc Clin Oncol 21:462 (Abstract 2539)Google Scholar
  43. Kosmidis P, Samantas E, Fountzilas G, Pavlidis N, Apostolopoulou F, Skarlos D (1994) Cisplatin/etoposide vs carboplatin/etoposide and irradiation in small-cell lung cancer: a randomized phase III study. Semin Oncol 21(Suppl. 6):23–30PubMedGoogle Scholar
  44. Lebeau B, Chastang CL, Allard P, Migueres J, Boita F, Fichet D (1992) Six vs twelve cycles for complete responders to chemotherapy in small cell lung cancer: definitive results of a randomised clinical trial. Eur Respir J 5:286–290PubMedGoogle Scholar
  45. Levitan N, Dowlati A, Shina D, Craffey M, Mackay W, DeVore R, Jett J, Remick SC, Chang A, Johnson D (2000) Multi-institutional pahse I/II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited-stage small-cell lung carcinoma. J Clin Oncol 18:1102–1109PubMedGoogle Scholar
  46. Leyvraz S, Pampallona S, Martinelli G, Ploner F, Perey L, Aversa S, Peters S, Brunsvig P, Montes A, Lange A, Yilmaz U, Rosti G; Solid Tumors Working Party of the European Group for Blood and Marrow Transplantation (2008) A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial. J Natl Cancer Inst 100:533–541PubMedCrossRefGoogle Scholar
  47. Liengswangwong V, Bonner JA, Shaw EG, Foote RL, Frytak S, Eagan RT, Jett JR, Richardson RL, Creagan ET, Su JQ (1994) Limited-stage small-cell lung cancer: patterns of intrathoracic recurrence and the implications for thoracic radiotherapy. J Clin Oncol 12:496–502PubMedGoogle Scholar
  48. Mascaux C, Paesmans M, Berghmans T, Branle F, Lafitte JJ, Lemaitre F, Meert AP, Vermylen P, Sculier JP, European Lung Cancer Working Party (ELCWP) (2000) A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer 30:23–36PubMedCrossRefGoogle Scholar
  49. Maurer LH, Tulloh M, Weiss R, Blom J, Leone L, Glidewell O, Pajak TF (1980) A randomized combined modality trial on small cell carcinoma of the lung. Cancer 45:30–39PubMedCrossRefGoogle Scholar
  50. Mavroudis D, Papadakis E, Veslemes M, Tsiafaki X, Stavrakakis J, Kouroussis C, Kakolyris S, Bania E, Jordanoglou J, Agelidou M, Vlachonicolis J, Georgoulias V (2001) A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer. Ann Oncol 12:463–470PubMedCrossRefGoogle Scholar
  51. Mehta C, Vogl SE, Farber S (1982) High-dose cyclophosphamide (c) in the induction (ind) chemotherapy (ct) of small cell lung cancer (sclc)–Minor improvements in rate of remission and survival. Proc Am Assoc Cancer Res 23:165Google Scholar
  52. Mennecier B, Jacoulet P, Dubiez A, Westeel V, Bosset JF, Magnin V, Depierre A (2000) Concurrent cisplatin/etoposide chemotherapy plus twice daily thoracic radiotherapy in limited stage small cell lung cancer: a phase II study. Lung Cancer 27:137–143PubMedCrossRefGoogle Scholar
  53. Miller KL, Marks LB, Sibley GS, Clough RW, Garst JL, Crawford J, Shafman TD (2003) Routine use of approximately 60 Gy once-daily thoracic irradiation for patients with limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys 56:355–359PubMedCrossRefGoogle Scholar
  54. Mira JG, Livingston RB (1980) Evaluation and radiotherapy implications of chest relapse patterns in small cell lung carcinoma treated with radiotherapy-chemotherapy: study of 34 cases and review of the literature. Cancer 46:2557–2565PubMedCrossRefGoogle Scholar
  55. Mulshine JL, Treston AM, Brown HP, Birer MJ, Shaw GL (1993) Initiators and promoters of lung cancer. Chest 103(Suppl. 1):4S–11SPubMedGoogle Scholar
  56. Murray N, Coy P, Pater J, Hodson I, Arnold A, Zee BC, Payne D, Kostashuk EC, Evans WK, Dixon P (1993) Importance of timing for thoracic irradiation in the combined modality treatment of limited stage small cell lung cancer. J Clin Oncol 11:336–344PubMedGoogle Scholar
  57. Niell HB, Herndon JE, Miller AA (2002) Randomized phase III intergroup trial (CALGB 9732) of etoposide and cisplatin with or without paclitaxel and G-CSF in patients with extensive stage small cell lung cancer. Proc Am Soc Clin Oncol 21:293aGoogle Scholar
  58. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S, Saijo N, The Japan Clinical Oncology Group (2002) Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346:85–91PubMedCrossRefGoogle Scholar
  59. Papac RJ, Son Y, Bien R, Tiedemann D, Keohane M, Yesner R (1987) Improved local control of thoracic disease in small-cell lung cancer with higher dose thoracic irradiation and cyclic chemotherapy. Int J Radiat Oncol Biol Phys 13:993–998PubMedCrossRefGoogle Scholar
  60. Perez CA, Krauss S, Bartolucci AA, Durant JR, Lowenbraun S, Salter MM, Storaalsi J, Kellermeyer R, Comas F (1981) Thoracic and elective brain irradiation with concomitant or delayed multiagent chemotherapy in the treatment of localized small cell carcinoma of the lung: a randomized prospective study by the southeastern cancer study group. Cancer 47:2407–2413PubMedCrossRefGoogle Scholar
  61. Perry MC, Eaton WL, Propert KJ, Ware JH, Zimmer B, Chahinian AP, Skarin A, Carey RW, Kreisman H, Faulkner C (1987) Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. N Engl J Med 316:912–918PubMedCrossRefGoogle Scholar
  62. Pignon JP, Arriagada R, Ihde DC, Johnson DH, Perry MC, Souhami RL, Brodin O, Joss RA, Kies MS, Lebeau B (1992) A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 327:1618–1627PubMedCrossRefGoogle Scholar
  63. Pijls-Johannesma MC, De Ruysscher D, Lambin P, Rutten I, Vansteenkiste JF (2005) Early versus late chest radiotherapy for limited stage small cell lung cancer. Cochrane Database Syst Rev 1:CD004700Google Scholar
  64. Pujol JL, Carestia L, Daurès JP (2000) Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br J Cancer 83:8–15PubMedCrossRefGoogle Scholar
  65. Reck M, von Pawel J, Macha HN (2003) Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carcoplatin, etoposide, and vincristine in patients with small-cell lung cancer. J Natl Cancer Inst 95:1118–1127PubMedCrossRefGoogle Scholar
  66. Roof KS, Fidias P, Lynch TJ, Ancukiewicz M, Choi NC (2003) Radiation dose escalation in limited-stage small-cell lung cancer. Int J Radiat Onmcol Biol Phys 57:701–708CrossRefGoogle Scholar
  67. Sandler AB (2003) Chemotherapy for small cell lung cancer. Sem Oncol 30:9–25CrossRefGoogle Scholar
  68. Sandler A, Declerck L, Wagner H (2000) A phase II study of cisplatin plus etoposide plus paclitaxel and concurrent radiation therapy for previously untreated limited stage small cell lung cancer (E2596): an eastern cooperative oncology group trial. Proc Am Soc Clin Oncol 19: 491a (Abstract 1920)Google Scholar
  69. Schild S, Brindle JS, Geyer SM (2003) Long-term results of a phase III trial comparing once a day radiotherapy (QD RT) or twice a day radiotherapy (BID RT) in limited stage small cell lung cancer (LSCLC). Proc Am Soc Clin Oncol 21 (Abstract 2536)Google Scholar
  70. Schiller JH, Adak S, Cella D, DeVore RF 3rd, Johnson DH (2001) Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593–a phase III trial of the eastern cooperative oncology group. J Clin Oncol 19:2114–2122PubMedGoogle Scholar
  71. Schultz HP, Nielsen OS, Sell A (1988) Timing of chest radiation with respect to combination chemotherapy in small cell lung cancer, limited disease. Lung Cancer 4:153 (Abstract)Google Scholar
  72. Sculier JP, Paesmans M, Bureau G, Giner V, Lecomte J, Michel J, Berchier MC, Van Cutsem O, Kustner U, Kroll F, Sergysels R, Mommen P, Klastersky J (1996) Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small-cell lung cancer. J Clin Oncol 14:2337–2344PubMedGoogle Scholar
  73. Segawa Y, Uoeka H, Kiura K, Tabata M, Takigawa N, Hiraki Y, Watanabe Y, Yonei T, Moritaka T, Hiyama J, Hiraki S, Tanimoto M, Harada M (2003) Phase I/II study of altered schedule of cisplatin and etoposide administration and concurrent accelerated hyperfractionated thoracic radiotherapy for limited-stage small-cell lung cancer. Lung Cancer 41:13–20PubMedCrossRefGoogle Scholar
  74. Shepherd FA, Crowley J, van Houtte P, Postmus PE, Carney D, Chansky K, Shaikh Z, Goldstraw P (2007) The international association for the study of lung cancer lung cancer stagign project proposals regarding teh clinical staging of small-cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol 2:1067–1077PubMedCrossRefGoogle Scholar
  75. Sloan JA, Bonner JA, Hillman SL, Allmer C, Shanahan TG, Brooks BJ, Marks RS, Vargas-Chanes D, Jett JR (2002) A quality-adjusted reanalysis of a phase III trial comparing once-daily thoracic radiation vs twice-daily thoracic radiation in patients with limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys 52:371–381PubMedCrossRefGoogle Scholar
  76. Spiro SG, Souhami RL, Geddes DM, Ash CM, Quinn H, Harper PG, Tobias JS, Partridge M, Eraut D (1989) Duration of chemotherapy in small cell lung caner: a cancer research campaign trial. Br J Cancer 59:578–583PubMedCrossRefGoogle Scholar
  77. Spiro SG, James LE, Rudd RM, Trask CW, Tobias JS, Snee M, Gilligan D, Murray PA, Ruiz de Elvira MC, O’Donnell KM, Gower NH, Harper PG, Hackshaw AK (2006) London lung cancer group early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer: a London lung cancer group multicenter randomized clinical trial and meta-analysis. J Clin Oncol 24:3823–3830PubMedCrossRefGoogle Scholar
  78. Steward WP, von Pawel J, Gatzemaier U, Woll P, Thatcher N, Koschel G, Clancy L, Verweij J, de Wit R, Pfeifer W, Fennelly J, von Eiff M, Frisch J (1998) Effects of granulocyte colony-stimulating factor and dose-intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomised study of 300 patients. J Clin Oncol 16:642–650PubMedGoogle Scholar
  79. Sundstrøm S, Bremnes RM, Kaasa S, Aasebø U, Hatlevoll R, Dahle R, Boye N, Wang M, Vigander T, Vilsvik J, Skovlund E, Hannisdal E, Aamdal S (2002) Norwegian lung cancer study group cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years’ follow-up. J Clin Oncol 20:4665–4672PubMedCrossRefGoogle Scholar
  80. Takada M, Fukuoka M, Kawahara M, Sugiiura T, Yokoyama A, Yokota S, Nishiwaki Y, Watanabe K, Noda K, Tamura T, Fukuda H, Saijo N (2002) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan clinical oncology group study 9104. J Clin Oncol 20:3054–3060PubMedCrossRefGoogle Scholar
  81. Thatcher N, Girling DJ, Howood P, Sambrook RJ, Qian W, Stephens RJ (2000) Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British medical research council multicenter randomised trial. J Clin Oncol 18:395–404PubMedGoogle Scholar
  82. Travis WD, Brambilla E, Muller-Hermlink HK, Harris CC (2004) World health organziation classification of tumours. Pathology and genetics of tumours of the lung, pleura, thymus and heart. IARC Press, LyonGoogle Scholar
  83. Turrisi AT, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, Wagner H, Aisner S, Johnson DH (1999) Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340:264–271CrossRefGoogle Scholar
  84. Videtic GMM, Truong PT, Dar AR, Yu EW, Stitt LW (2003) Shifting from hypofractionated to “conventionally” fractionated thoracic radiotherapy: a single institutions’s 10-year experience in the management of limited-stage small-cell lung cancer using concurrent chemoradiation. Int J Radiat Oncol Biol Phys 57:709–716PubMedCrossRefGoogle Scholar
  85. Videtic GM, Belderbos JS, Spring Kong FM, Kepka L, Martel MK, Jeremic B (2008) Report from the international atomic energy agency (IAEA) consultants’ meeting on elective nodal irradiation in lung cancer: small-cell lung cancer (SCLC). Int J Radiat Oncol Biol Phys 72:327–334PubMedCrossRefGoogle Scholar
  86. Warde P, Payne D (1992) Does thoracic radiation improve survival and local control in limited-stage small cell carcinoma of the lung? J Clin Oncol 10:890–895PubMedGoogle Scholar
  87. Watkins JM, Fortney JA, Wahlquist AE, Shirai K, Garrett-Mayer E, Aguero EG, Sherman CA, Turrisi AT 3rd, Sharma AK (2010a) Once-daily radiotherapy to > or = 59.4 Gy versus twice-daily radiotherapy to > or = 45.0 Gy with concurrent chemotherapy for limited-stage small-cell lung cancer: a comparative analysis of toxicities and outcomes. Jpn J Radiol 28:340–348PubMedCrossRefGoogle Scholar
  88. Watkins JM, Wahlquist AE, Zauls AJ, Shirai K, Garrett-Mayer E, Aguero EG, Silvestri GA, Sherman CA, Sharma AK (2010b) Involved-field radiotherapy with concurrent chemotherapy for limited-stage small-cell lung cancer: disease control, patterns of failure and survival. J Med Imaging Radiat Oncol 54:483–489PubMedCrossRefGoogle Scholar
  89. White JE, Chen T, McCracken J, Kennedy P, Seydel HG, Hartman G, Mira J, Khan M, Durrance FY, Skinner O (1982) The influence of radiation therapy quality control on survival, response, and sites in oat cell carcinoma of the lung. Preliminary report of a southwest oncology group study. Cancer 50:1084–1090PubMedCrossRefGoogle Scholar
  90. Woo IS, Park YS, Kwon SH, Park YL, Lee JA, Park MJ, Hyun IG, Jung KS, Bae HS, Oh DH, Kim WS, Park K, Park CH, Kim HJ, Ahn YC (2000) A phase II study of VP-16-ifosfamide-cisplatin combination chemotherapy plus early concurrent thoracic irradiation for previously untreated limited small cell lung cancer. Jpn J Clin Oncol 30:542–546PubMedCrossRefGoogle Scholar
  91. Woods RL, Levi JA (1984) Chemotherapy for small cell lung cancer (SCLC): A randomised study of maintenance therapy with cyclophosphamide, adriamycin and vincristine (CAV) after remission induction with cis-platinum (CIS-DDP), VP 16–213 and radiotherapy. Proc Am Soc Clin Oncol 3:214Google Scholar
  92. Work E, Nielsen O, Bentzen S, Fode K, Palshof T (1997) Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small cell lung cancer. J Clin Oncol 15:3030–3037PubMedGoogle Scholar
  93. Yilmaz U, Anar C, Korkmaz E, Yapicioglu S, Karadogan I, Ozkök S (2010) Carboplatin and etoposide followed by once-daily thoracic radiotherapy in limited disease small-cell lung cancer: unsatisfactory results. Tumori 96:234–240PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2011

Authors and Affiliations

  • Branislav Jeremić
    • 1
  • Željko Dobrić
    • 1
  • Francesc Casas
    • 2
  1. 1.Institute of Lung DiseasesSremska KamenicaSerbia
  2. 2.University ClinicBarcelonaSpain

Personalised recommendations